Marshall Wace LLP Acquires Shares of 288,992 Zai Lab Limited (NASDAQ:ZLAB)

Marshall Wace LLP bought a new position in Zai Lab Limited (NASDAQ:ZLAB - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 288,992 shares of the company's stock, valued at approximately $7,569,000. Marshall Wace LLP owned about 0.26% of Zai Lab at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. purchased a new stake in Zai Lab during the 4th quarter valued at about $46,172,000. Raymond James Financial Inc. purchased a new stake in shares of Zai Lab during the fourth quarter valued at approximately $1,032,000. Alberta Investment Management Corp increased its position in shares of Zai Lab by 42.9% during the fourth quarter. Alberta Investment Management Corp now owns 232,293 shares of the company's stock valued at $6,084,000 after acquiring an additional 69,740 shares in the last quarter. Geode Capital Management LLC raised its holdings in Zai Lab by 26.4% in the 3rd quarter. Geode Capital Management LLC now owns 43,626 shares of the company's stock worth $1,053,000 after acquiring an additional 9,107 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its position in Zai Lab by 28.9% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 183,317 shares of the company's stock valued at $4,801,000 after acquiring an additional 41,128 shares in the last quarter. 41.65% of the stock is currently owned by institutional investors.

Insider Activity at Zai Lab

In related news, insider Rafael Amado sold 3,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $38.41, for a total transaction of $115,230.00. Following the completion of the transaction, the insider now directly owns 30,834 shares in the company, valued at approximately $1,184,333.94. The trade was a 8.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Ying Du sold 50,000 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the sale, the chief executive officer now owns 494,117 shares in the company, valued at approximately $17,032,212.99. The trade was a 9.19 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 138,744 shares of company stock worth $4,685,294. Corporate insiders own 13.88% of the company's stock.

Zai Lab Stock Performance

ZLAB stock opened at $32.53 on Wednesday. The company has a market cap of $3.57 billion, a price-to-earnings ratio of -11.74 and a beta of 1.09. The business's 50-day moving average is $33.08 and its two-hundred day moving average is $29.34. Zai Lab Limited has a fifty-two week low of $15.00 and a fifty-two week high of $39.77.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). The business had revenue of $109.07 million for the quarter, compared to analysts' expectations of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. Equities analysts predict that Zai Lab Limited will post -2.58 earnings per share for the current year.

Analysts Set New Price Targets

ZLAB has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, March 13th. Scotiabank assumed coverage on Zai Lab in a report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price objective for the company. Cantor Fitzgerald restated an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th. Finally, Bank of America reiterated a "neutral" rating and issued a $36.10 price target (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

Want to see what other hedge funds are holding ZLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zai Lab Limited (NASDAQ:ZLAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.